# Research Peptide Fundamentals, Checked at the Source > Research Peptide Fundamentals Research Peptides — Right Peptides — Research Peptide Fundamentals research peptides: an independent, source-linked guide to KPV, semaglutide, CJC-1295, and NAD+. **CLAIM DESK / FOUR RESEARCH RECORDS** Four unlike compounds, one disciplined method: identify the model, name the endpoint, and follow the conclusion back to the cited record. ### [KPV](/kpv) ![KPV research illustration](images/kpv.webp) A melanocortin-derived tripeptide with anti-inflammatory findings in cells and animal models, but no established human clinical evidence. ### [Semaglutide](/semaglutide) ![Semaglutide research illustration](images/semaglutide.webp) A GLP-1 receptor agonist supported by large randomized trials across weight, cardiovascular, and kidney outcomes. ### [CJC-1295](/cjc-1295) ![CJC-1295 research illustration](images/cjc-1295.webp) A long-acting GHRH analogue that raises the GH/IGF-1 axis, supported mainly by small, early human pharmacology studies. ### [NAD+](/nad) ![NAD+ research illustration](images/nad.webp) A cellular coenzyme rather than a peptide; human supplementation research primarily examines the precursors NMN and NR. ## The short version Right Peptides is a reference desk for claims, not a product catalogue. It brings four very different research records into the same view: KPV, semaglutide, CJC-1295, and NAD+. The point is not to rank them by popularity. It is to ask the same basic questions of each claim. **What was studied? In what model or population? What endpoint changed? Which source supports the statement?** That method quickly reveals why broad labels can mislead. KPV has promising anti-inflammatory results, but chiefly in cells and animal models [1][2][3][4]. Semaglutide has large randomized human outcome trials [9][10][11]. CJC-1295 has small human studies showing biological activity, not a mature therapeutic evidence base [15][16][17]. NAD+ is not a peptide at all, and much of its human supplementation literature concerns precursors rather than NAD+ itself [18][19][20][22]. This desk keeps those distinctions visible. It offers research context, not personal medical advice or a recommendation to use any compound. ## The three-part claim check A research statement is only as useful as the path back to its evidence. Right Peptides uses a simple three-part check. 1. **Model:** Was the work done in a test tube, an animal model, a small pharmacology study, or a randomized human trial? A result in cultured intestinal cells can clarify a mechanism, but it cannot establish a human benefit. 2. **Endpoint:** Did investigators measure a signaling pathway, a laboratory marker, a patient-reported outcome, or a major clinical event? Moving a biomarker and preventing a clinical event are different achievements. 3. **Source:** Does the conclusion match the cited paper, including its population, comparator, and limits? A citation should make a claim inspectable rather than decorate it. Applied consistently, this framework prevents a common error: carrying a precise finding into a broader setting where it has not been tested. KPV's PepT1 uptake and inflammatory-signaling findings came from cellular and mouse work [3]. Semaglutide's cardiovascular result came from a large defined human population with established cardiovascular disease [10]. CJC-1295's record establishes sustained GH and IGF-1 stimulation in healthy adults [16][17]. NAD+ precursor trials show changes in blood NAD+ or selected metabolic endpoints, while a current review finds clinical efficacy limited and tissue data sparse [18]. Each conclusion stays attached to its model and endpoint. ## What are research peptides? Peptides are short chains of amino acids. Some act as signals in the body; laboratory analogues may be designed to resist breakdown, bind a receptor longer, or test a biological pathway. The term *research peptide* can refer to a molecule studied only in laboratory settings, an investigational molecule tested in people, or a peptide that is also an approved prescription medicine. Those categories do not carry the same evidence or regulatory status. This collection makes the category boundary visible. KPV is a three-amino-acid fragment derived from alpha-melanocyte-stimulating hormone. CJC-1295 is a modified analogue of growth-hormone-releasing hormone. Semaglutide is a modified peptide medicine that activates the GLP-1 receptor. NAD+, by contrast, is a dinucleotide coenzyme, not a peptide; it appears here because it is often grouped into the same longevity and wellness research conversation. A careful digest should correct that taxonomy instead of repeating it. The word *research* also does not mean that every commercial material has been clinically tested. Evidence about a defined compound in a controlled study does not automatically transfer to an unverified preparation. The compound pages therefore separate identity, mechanism, measured findings, reported experiences, safety, and regulatory context. ## Four records, four levels of certainty [KPV](/kpv) leads this desk because it is a useful test of evidence discipline. Its literature supports anti-inflammatory mechanisms and delivery strategies in preclinical models, including targeted colitis formulations [1][2][3]. That is scientifically meaningful without being a clinical treatment claim. [Semaglutide](/semaglutide) sits at the clinical end of the spectrum. Large trials report defined weight, cardiovascular, and kidney outcomes in specified adult populations [9][10][11]. Its safety record is also far more developed, including gastrointestinal and biliary concerns described in a dedicated review [12]. [CJC-1295](/cjc-1295) occupies the middle: human pharmacology studies show that it can produce sustained changes in growth hormone and IGF-1 while preserving pulsatile secretion [16][17], but the evidence is small and early. An analytical study also identified it in an unknown preparation from an anti-doping context, underscoring identity and provenance concerns [14]. [NAD+](/nad) requires a category correction and an endpoint correction. It is a central cellular coenzyme [21]. Oral precursor trials show that NMN or NR can raise NAD+ measures and affect selected endpoints [19][20][22], but a current review concludes that human efficacy remains limited and tissue-specific evidence is sparse [18]. The [comparison](/compare) keeps all four records aligned without pretending they answer the same question. --- Right Peptides is an independent claim-checking digest that keeps each peptide conclusion attached to its model, endpoint, and source—not a shop or medical service.